Oppenheimer Initiates Coverage On Crinetics Pharmaceuticals with Outperform Rating, Announces Price Target of $40
Portfolio Pulse from richadhand@benzinga.com
Oppenheimer analyst Leland Gershell has initiated coverage on Crinetics Pharmaceuticals with an Outperform rating and a price target of $40.
August 31, 2023 | 8:29 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Crinetics Pharmaceuticals has been given an Outperform rating and a price target of $40 by Oppenheimer.
The Outperform rating and price target of $40 by Oppenheimer indicates a positive outlook for Crinetics Pharmaceuticals. This could lead to increased investor interest and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100